2017 is an important year for the international nephrology community. March 9 was World Kidney Day, the theme this year being ‘Kidney disease and obesity: healthy lifestyles for healthy kidneys’, ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

People with chronic kidney disease (CKD) have less phosphate removal from their body via the kidneys, so that phosphate levels in the blood and in body tissues increase as kidney function decreases.

"Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, ...

Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage ...

Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, ...

Some women may be unaware they’re living with risks for heart disease, kidney disease and metabolic conditions like diabetes, ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...